Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Enzynorm is a fixed combination pharmaceutical product containing pepsin and betaine hydrochloride (often referred to as amino acid hydrochloride). It is primarily indicated for the treatment of functional dyspepsia and other digestive disorders associated with gastric hypoacidity (low stomach acid production). Pepsin serves as a proteolytic enzyme that initiates the breakdown of dietary proteins into smaller peptides in the stomach. Betaine hydrochloride acts as an acidifying agent, lowering the gastric pH to provide the optimal acidic environment necessary for the activation of pepsinogen into pepsin and for the subsequent enzymatic activity of pepsin. This combination helps alleviate symptoms such as bloating, postprandial fullness, and upper abdominal pain by supporting the initial stages of protein digestion in patients with impaired gastric secretion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Enzynorm.